Degarelix

Prostate cancer is a high-incidence malignant tumor of the genitourinary system among men worldwide. Patients at advanced stages often require long-term androgen deprivation therapy to maintain stable disease conditions, and the advent of degarelix provides a safer medication option for this population. As a gonadotropin-releasing hormone (GnRH) receptor antagonist, it competitively binds to GnRH receptors on the pituitary gland to rapidly inhibit the secretion of luteinizing hormone and follicle-stimulating hormone, thereby rapidly reducing testosterone levels without the testosterone "flare" phenomenon that occurs in the initial stage of traditional GnRH agonists, making it especially suitable for advanced prostate cancer patients who need rapid testosterone reduction, have bone metastasis risk or are intolerant to agonists.

The global degarelix market size maintains a steady growth trend. The market size in 2023 was approximately USD 1.27 billion, and the compound annual growth rate from 2024 to 2030 is expected to be around 4.8%. With the continuous rise in the global prevalence of prostate cancer and the improvement of patients' requirements for the safety of castration therapy, there is still considerable room for the release of clinical demand. In the domestic market, original research products currently dominate, and multiple pharmaceutical companies have arranged for generic drug research and development. Since 2023, domestic generic drug preparations have passed the consistency evaluation and been launched. Subsequently, with the increase of generic drug penetration rate, the overall medication accessibility will be significantly improved.

The original research enterprise of degarelix is Ferring Pharmaceuticals, with the original research trade name "Firmagon". Its core compound patent in the United States expired in 2024, and the expiration date of the core compound patent in China is 2027. The main dosage form approved for the original research product is powder for injection, with specifications of 80mg and 120mg. It has been included in the *Catalogue of Reference Preparations of Chemical Drugs* of China, and is also listed as a reference preparation by the FDA. Up to now, the degarelix active pharmaceutical ingredients (APIs) of multiple domestic enterprises have completed registration at the Center for Drug Evaluation (CDE) and been publicized as Class A status, and multiple domestic generic drug preparations have been approved for marketing. (Data as of October 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of degarelix impurity reference standards. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. They comply with multiple regulations including the Chinese Pharmacopoeia and FDA regulations, which can fully meet the reference standard needs of pharmaceutical enterprises in the whole process of API research and development, quality research and preparation declaration, and help enterprises accelerate the product launch progress.